312 related articles for article (PubMed ID: 29751114)
1. Very Low Numbers of CD4
Copsel S; Wolf D; Kale B; Barreras H; Lightbourn CO; Bader CS; Alperstein W; Altman NH; Komanduri KV; Levy RB
Biol Blood Marrow Transplant; 2018 Sep; 24(9):1788-1794. PubMed ID: 29751114
[TBL] [Abstract][Full Text] [Related]
2. BET Bromodomain Inhibitors Which Permit Treg Function Enable a Combinatorial Strategy to Suppress GVHD in Pre-clinical Allogeneic HSCT.
Copsel SN; Lightbourn CO; Barreras H; Lohse I; Wolf D; Bader CS; Manov J; Kale BJ; Shah D; Brothers SP; Perez VL; Komanduri KV; Wahlestedt C; Levy RB
Front Immunol; 2018; 9():3104. PubMed ID: 30733722
[TBL] [Abstract][Full Text] [Related]
3. Marked in Vivo Donor Regulatory T Cell Expansion via Interleukin-2 and TL1A-Ig Stimulation Ameliorates Graft-versus-Host Disease but Preserves Graft-versus-Leukemia in Recipients after Hematopoietic Stem Cell Transplantation.
Wolf D; Barreras H; Bader CS; Copsel S; Lightbourn CO; Pfeiffer BJ; Altman NH; Podack ER; Komanduri KV; Levy RB
Biol Blood Marrow Transplant; 2017 May; 23(5):757-766. PubMed ID: 28219835
[TBL] [Abstract][Full Text] [Related]
4. Activation of the DR3-TL1A Axis in Donor Mice Leads to Regulatory T Cell Expansion and Activation With Reduction in Graft-Versus-Host Disease.
Mavers M; Simonetta F; Nishikii H; Ribado JV; Maas-Bauer K; Alvarez M; Hirai T; Turkoz M; Baker J; Negrin RS
Front Immunol; 2019; 10():1624. PubMed ID: 31379829
[TBL] [Abstract][Full Text] [Related]
5. Blockade of chronic graft-versus-host disease by alloantigen-induced CD4+CD25+Foxp3+ regulatory T cells in nonlymphopenic hosts.
Giorgini A; Noble A
J Leukoc Biol; 2007 Nov; 82(5):1053-61. PubMed ID: 17684039
[TBL] [Abstract][Full Text] [Related]
6. Treatment with agonistic DR3 antibody results in expansion of donor Tregs and reduced graft-versus-host disease.
Kim BS; Nishikii H; Baker J; Pierini A; Schneidawind D; Pan Y; Beilhack A; Park CG; Negrin RS
Blood; 2015 Jul; 126(4):546-57. PubMed ID: 26063163
[TBL] [Abstract][Full Text] [Related]
7. Induced regulatory T cells promote tolerance when stabilized by rapamycin and IL-2 in vivo.
Zhang P; Tey SK; Koyama M; Kuns RD; Olver SD; Lineburg KE; Lor M; Teal BE; Raffelt NC; Raju J; Leveque L; Markey KA; Varelias A; Clouston AD; Lane SW; MacDonald KP; Hill GR
J Immunol; 2013 Nov; 191(10):5291-303. PubMed ID: 24123683
[TBL] [Abstract][Full Text] [Related]
8. Amelioration of acute graft-versus-host disease by adoptive transfer of ex vivo expanded human cord blood CD4+CD25+ forkhead box protein 3+ regulatory T cells is associated with the polarization of Treg/Th17 balance in a mouse model.
Yang J; Fan H; Hao J; Ren Y; Chen L; Li G; Xie R; Yang Y; Qian K; Liu M
Transfusion; 2012 Jun; 52(6):1333-47. PubMed ID: 22098312
[TBL] [Abstract][Full Text] [Related]
9. Regulatory T Cell Amelioration of Graft-versus-Host Disease following Allogeneic/Xenogeneic Hematopoietic Stem Cell Transplantation Using Mobilized Mouse and Human Peripheral Blood Donors.
Barreras H; Copsel SN; Bader CS; Ding Y; Wolf D; Cash C; Stacey CJ; Benjamin C; Seavey MM; Wolf J; Jasuja RR; Pfeiffer B; Hill GR; Komanduri KV; Jurecic R; Malek TR; Levy RB
Transplant Cell Ther; 2023 May; 29(5):341.e1-341.e9. PubMed ID: 36804930
[TBL] [Abstract][Full Text] [Related]
10. Rorc restrains the potency of ST2+ regulatory T cells in ameliorating intestinal graft-versus-host disease.
Yang J; Ramadan A; Reichenbach DK; Loschi M; Zhang J; Griesenauer B; Liu H; Hippen KL; Blazar BR; Paczesny S
JCI Insight; 2019 Mar; 4(5):. PubMed ID: 30694220
[TBL] [Abstract][Full Text] [Related]
11. Host natural killer T cells induce an interleukin-4-dependent expansion of donor CD4+CD25+Foxp3+ T regulatory cells that protects against graft-versus-host disease.
Pillai AB; George TI; Dutt S; Strober S
Blood; 2009 Apr; 113(18):4458-67. PubMed ID: 19221040
[TBL] [Abstract][Full Text] [Related]
12. Blockade of interleukin-27 signaling reduces GVHD in mice by augmenting Treg reconstitution and stabilizing Foxp3 expression.
Belle L; Agle K; Zhou V; Yin-Yuan C; Komorowski R; Eastwood D; Logan B; Sun J; Ghilardi N; Cua D; Williams CB; Gaignage M; Marillier R; van Snick J; Drobyski WR
Blood; 2016 Oct; 128(16):2068-2082. PubMed ID: 27488350
[TBL] [Abstract][Full Text] [Related]
13. CD8+ Foxp3+ regulatory T cells are induced during graft-versus-host disease and mitigate disease severity.
Beres AJ; Haribhai D; Chadwick AC; Gonyo PJ; Williams CB; Drobyski WR
J Immunol; 2012 Jul; 189(1):464-74. PubMed ID: 22649199
[TBL] [Abstract][Full Text] [Related]
14. TNF-α priming enhances CD4+FoxP3+ regulatory T-cell suppressive function in murine GVHD prevention and treatment.
Pierini A; Strober W; Moffett C; Baker J; Nishikii H; Alvarez M; Pan Y; Schneidawind D; Meyer E; Negrin RS
Blood; 2016 Aug; 128(6):866-71. PubMed ID: 27365424
[TBL] [Abstract][Full Text] [Related]
15. Peri-alloHCT IL-33 administration expands recipient T-regulatory cells that protect mice against acute GVHD.
Matta BM; Reichenbach DK; Zhang X; Mathews L; Koehn BH; Dwyer GK; Lott JM; Uhl FM; Pfeifer D; Feser CJ; Smith MJ; Liu Q; Zeiser R; Blazar BR; Turnquist HR
Blood; 2016 Jul; 128(3):427-39. PubMed ID: 27222477
[TBL] [Abstract][Full Text] [Related]
16. Dendritic cells control CD4+CD25+ Treg cell suppressor function in vitro through juxtacrine delivery of IL-2.
Kulhankova K; Rouse T; Nasr ME; Field EH
PLoS One; 2012; 7(9):e43609. PubMed ID: 22984435
[TBL] [Abstract][Full Text] [Related]
17. Ex vivo expanded human CD4+CD25+Foxp3+ regulatory T cells prevent lethal xenogenic graft versus host disease (GVHD).
Cao T; Soto A; Zhou W; Wang W; Eck S; Walker M; Harriman G; Li L
Cell Immunol; 2009; 258(1):65-71. PubMed ID: 19410243
[TBL] [Abstract][Full Text] [Related]
18. Generation of Human Alloantigen-Specific Regulatory T Cells Under Good Manufacturing Practice-Compliant Conditions for Cell Therapy.
Cheraï M; Hamel Y; Baillou C; Touil S; Guillot-Delost M; Charlotte F; Kossir L; Simonin G; Maury S; Cohen JL; Lemoine FM
Cell Transplant; 2015; 24(12):2527-40. PubMed ID: 25198125
[TBL] [Abstract][Full Text] [Related]
19. Clinical-Grade Expanded Regulatory T Cells Are Enriched with Highly Suppressive Cells Producing IL-10, Granzyme B, and IL-35.
Ulbar F; Villanova I; Giancola R; Baldoni S; Guardalupi F; Fabi B; Olioso P; Capone A; Sola R; Ciardelli S; Del Papa B; Brattelli A; Ricciardi I; Taricani S; Sabbatinelli G; Iuliani O; Passeri C; Sportoletti P; Santarone S; Pierini A; Calabrese G; Falzetti F; Bonfini T; Accorsi P; Ruggeri L; Martelli MF; Velardi A; Di Ianni M
Biol Blood Marrow Transplant; 2020 Dec; 26(12):2204-2210. PubMed ID: 32961369
[TBL] [Abstract][Full Text] [Related]
20. Superior immune reconstitution using Treg-expanded donor cells versus PTCy treatment in preclinical HSCT models.
Wolf D; Bader CS; Barreras H; Copsel S; Pfeiffer BJ; Lightbourn CO; Altman NH; Komanduri KV; Levy RB
JCI Insight; 2018 Oct; 3(20):. PubMed ID: 30333311
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
